

# **Terumo Announces Voting Results for the Election of Directors**

TOKYO, JAPAN – June 25, 2020 – Terumo Corporation (TSE: 4543) hereby announces the voting results for the election of directors at its Annual General Meeting of Shareholders held on June 25. All eight of the candidates listed on May 14 were elected as directors of Terumo Corporation. The three directors serving as Audit and Supervisory Committee members, elected on June 21, 2019, continue to hold office.

## 1. Directors

### (Excluding directors who serve as Audit and Supervisory Committee Members)

Name	New position	Current position
Takayoshi Mimura	Chairman of the Board	Same as on the left
Shinjiro Sato	President and CEO	Same as on the left
Toshiaki Takagi	Director and Senior Managing Executive Officer	Same as on the left
Shoji Hatano	Director and Managing Executive Officer	Same as on the left
Kyo Nishikawa	Director and Senior Executive Officer	Same as on the left
Ryuzo Ueda	Independent Director	Same as on the left
Yukiko Kuroda	Independent Director	Same as on the left
Hidenori Nishi	Independent Director	(New Director)

### 2. Directors who serve as Audit and Supervisory Committee Members

Name	Current position	
Yoshihiro Kimura	Director who serves as an Audit and Supervisory Committee Member	
Masaichi Nakamura	Independent director who serves as an Audit and Supervisory Committee Member	
Soichiro Uno	Independent director who serves as an Audit and Supervisory Committee Member	

#### **About Terumo**

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.

###